Stocktoria
Cullinan Therapeutics, Inc. CGEM
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-08
Cullinan Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $18.9M | $0 |
| R&D expense | $187.4M | $142.9M | $148.2M | $91.9M | $57.8M | $43.2M |
| Operating income | -$241.6M | -$196.9M | -$191.1M | $144.6M | -$68.0M | -$60.3M |
| Income tax | $0 | $117,000 | -$14.1M | $42.1M | $0 | — |
| Net income | -$219.9M | -$167.4M | -$153.2M | $111.2M | -$65.6M | -$51.8M |
| EPS (diluted) | — | — | $-3.69 | $2.38 | $-1.52 | — |
| Operating cash flow | -$175.8M | -$145.3M | -$134.3M | -$126.7M | -$43.4M | -$29.8M |
| Free cash flow | -$175.8M | -$145.3M | -$134.5M | -$127.8M | -$43.4M | -$29.8M |
| Cash & equivalents | $88.3M | $83.0M | $98.4M | $156.2M | $59.8M | $168.2M |
| Total assets | $448.4M | $621.8M | $484.2M | $561.1M | $437.2M | $214.7M |
| Total liabilities | $39.6M | $31.5M | $30.3M | $26.1M | $11.8M | $14.4M |
| Shareholders' equity | $408.7M | $590.3M | $453.9M | $535.0M | $425.4M | $200.3M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | -100.0% | — | — |
| Net income growth | — | — | -237.7% | — | — | — |
| EPS growth | — | — | -255.0% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.